TSXV:APC

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Advanced Proteome Therapeutics

Executive Summary

Advanced Proteome Therapeutics Corporation, through its subsidiary, Advanced Proteome Therapeutics Inc., operates as a biotechnology company in the United States.


Snowflake Analysis

Imperfect balance sheet and overvalued.

Share Price & News

How has Advanced Proteome Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: APC's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

8.3%

APC

-20.3%

CA Biotechs

0.8%

CA Market


1 Year Return

-31.6%

APC

17.7%

CA Biotechs

-11.3%

CA Market

Return vs Industry: APC underperformed the Canadian Biotechs industry which returned 17.7% over the past year.

Return vs Market: APC underperformed the Canadian Market which returned -11.3% over the past year.


Shareholder returns

APCIndustryMarket
7 Day8.3%-20.3%0.8%
30 Day8.3%-16.3%1.8%
90 Day188.9%-11.3%9.5%
1 Year-31.6%-31.6%17.7%17.7%-8.2%-11.3%
3 Year-78.3%-78.3%21.9%21.9%4.1%-5.8%
5 Year-90.0%-90.0%-53.1%-53.1%21.6%3.2%

Price Volatility Vs. Market

How volatile is Advanced Proteome Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Advanced Proteome Therapeutics undervalued compared to its fair value and its price relative to the market?

3.29x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate APC's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate APC's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: APC is unprofitable, so we can't compare its PE Ratio to the XN Biotechs industry average.

PE vs Market: APC is unprofitable, so we can't compare its PE Ratio to the Canadian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate APC's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: APC is good value based on its PB Ratio (3.3x) compared to the CA Biotechs industry average (4.2x).


Next Steps

Future Growth

How is Advanced Proteome Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

27.7%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Advanced Proteome Therapeutics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Advanced Proteome Therapeutics performed over the past 5 years?

13.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: APC is currently unprofitable.

Growing Profit Margin: APC is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: APC is unprofitable, but has reduced losses over the past 5 years at a rate of 13.3% per year.

Accelerating Growth: Unable to compare APC's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: APC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.5%).


Return on Equity

High ROE: APC's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Next Steps

Financial Health

How is Advanced Proteome Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: APC has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: APC has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: APC has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: APC's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: APC has sufficient cash runway for 1 months based on last reported free cash flow, but has since raised additional capital.

Forecast Cash Runway: APC is forecast to have sufficient cash runway for 1 months based on free cash flow estimates, but has since raised additional capital.


Next Steps

Dividend

What is Advanced Proteome Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate APC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate APC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if APC's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if APC's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of APC's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.6yrs

Average management tenure


CEO

Paul John Woodward (58yo)

1.58yrs

Tenure

US$82,063

Compensation

Mr. Paul John Courtney Woodward serves as President, Chief Executive Officer and Director at Aether Catalyst Solutions, Inc. since July 2014. Mr. Woodward serves as the President and Director of Conation C ...


CEO Compensation Analysis

Compensation vs Market: Paul John's total compensation ($USD82.06K) is below average for companies of similar size in the Canadian market ($USD175.28K).

Compensation vs Earnings: Paul John's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Paul John Woodward
President1.58yrsUS$82.06k0.77% $27.0k
Kenneth Phillippe
Chief Financial Officer11.33yrsUS$24.76k0.37% $13.0k
Martin John Woodward
Secretary & Director1.58yrsUS$15.06k1.1% $38.6k

1.6yrs

Average Tenure

58yo

Average Age

Experienced Management: APC's management team is not considered experienced ( 1.6 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Paul John Woodward
President1.58yrsUS$82.06k0.77% $27.0k
Martin John Woodward
Secretary & Director1.58yrsUS$15.06k1.1% $38.6k
David Webb
Member of Corporate Advisory Board5.33yrsno datano data
William Catalano
Independent Director1.58yrsno data0.59% $20.7k
William Dickie
Director2.08yrsno datano data
Paul Wender
Member of Scientific Advisory Board2.5yrsno datano data
Greg Thurber
Member of Scientific Advisory Board2.17yrsno datano data
Benjamin Krantz
Director2.33yrsno datano data

2.2yrs

Average Tenure

58yo

Average Age

Experienced Board: APC's board of directors are not considered experienced ( 2.2 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: APC insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 28.4%.


Top Shareholders

Company Information

Advanced Proteome Therapeutics Corporation's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Advanced Proteome Therapeutics Corporation
  • Ticker: APC
  • Exchange: TSXV
  • Founded:
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: CA$3.505m
  • Shares outstanding: 26.96m
  • Website: https://www.advancedproteome.com

Location

  • Advanced Proteome Therapeutics Corporation
  • 650 Albany Street
  • Suite 109
  • Boston
  • Massachusetts
  • 2118
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
APTC.FOTCPK (Pink Sheets LLC)YesCommon SharesUSUSDSep 1989
APCTSXV (TSX Venture Exchange)YesCommon SharesCACADSep 1989
0DB (Deutsche Boerse AG)YesCommon SharesDEEURSep 1989
0BST (Boerse-Stuttgart)YesCommon SharesDEEURSep 1989
0MUN (Boerse Muenchen)YesCommon SharesDEEURSep 1989

Biography

Advanced Proteome Therapeutics Corporation, through its subsidiary, Advanced Proteome Therapeutics Inc., operates as a biotechnology company in the United States. The company develops and commercializes a platform that is intended for the chemical modification of protein therapeutics, primarily antibody-drug conjugates. Its proprietary technology targets delivery of anti-cancer drugs to cancerous tumors. The company is headquartered in Boston, Massachusetts. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/07/14 00:20
End of Day Share Price2020/07/13 00:00
Earnings2020/04/30
Annual Earnings2019/07/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.